FDA OKs Gilead's Sovaldi and Harvoni for adolescents as young as 12 years old

|About: Gilead Sciences, Inc. (GILD)|By:, SA News Editor

The FDA approves the use of Gilead Sciences' (GILD +0.2%) hepatitis C meds Sovaldi (sofosbuvir) and Harvoni (ledipasvir and sofosbuvir) in patients aged 12 to 17. The two drugs were previously approved for use in adults only.